Get started
Author

Miriam Dorta

OA12.05 APOLO: Phase II Trial of Induction Chemo-Immunotherapy Plus Chemoradiotherapy and Maintenance Immunotherapy in Stage III NSCLC
2024 · M. Provencio, B. Campos, et al. · Journal of Thoracic Oncology · 25
The state of the art of EGFR exon 20 insertions in non-small cell lung cancer: Diagnosis and future perspectives
2023 · Miriam Dorta-Suárez, Maria de Miguel, et al. · Cancer Treatment Reviews · 25
PDF
Induction chemo-immunotherapy followed by chemo-radiotherapy and immunotherapy maintenance in stage III NSCLC (APOLO): a phase 2 trial
2025 · Mariano Provencio, Begoña Campos, et al. · Nature Communications · 18
PDF
Multimodality treatment in synchronous oligometastatic NSCLC: Analysis of the ETOP CHESS trial
2025 · Matthias Guckenberger, Isabelle Opitz, et al. · Lung Cancer · 10
EP08.02-149 Spanish Multicenter Retrospective Study of Real-Life Experience of Advanced NSCLC with EGFR Exon 20 Insertions Treated With Amivantamab
2022 · V. Albarrán-Artahona, J. Torres-Jiménez, et al. · Journal of Thoracic Oncology · 2
PDF
Normalized administered atezolizumab dose and clinical outcomes in advanced solid tumors: an exploratory analysis of the phase I PCD4989g study
2026 · V. Moreno, M. Dorta, et al. · Immuno-Oncology Technology
PDF
P1.16-02 Clinical Utility of ctDNA in Advanced NSCLC at Diagnosis or Where Insufficient Tissue Was Available, Based on the ESMO ESCAT Scale
2022 · L. Mezquita, M. Riudavets, et al. · Journal of Thoracic Oncology
Works count: 8
Citation count: 80
H-index: 4
I10-index: 4
Year
Topic
Type